Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819000 · ClinicalTrials.gov registry record
Therapy Optimization in Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by Teva Neuroscience.
- Completed
- Registry status
- 2,878
- Enrollment target
- 3
- Study locations
NCT00819000 is a study of Multiple Sclerosis that has completed, run by Teva Neuroscience. The registered enrollment target is 2,878 participants, above the 576-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (400% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00819000, a study of Multiple Sclerosis, has completed, sponsored by Teva Neuroscience.
- COMPLETED
- Registry status
- 2,878 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Conditions Studied
Interventions
- DRUG Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Study Locations (3)
Michigan
- Teva Investigational Site - Swartz Creek
Ohio
- Teva Investigational Site - Columbus
Pennsylvania
- Teva Investigational Site - Carnegie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,878 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819000
The ClinicalTrials.gov registry entry for NCT00819000 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,878 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 576-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (400% higher). The listed sponsor is Teva Neuroscience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b is the first listed.
NCT00819000 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00819000 about?
NCT00819000 is a clinical study titled "Therapy Optimization in Multiple Sclerosis (MS)". The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
What is the current status of trial NCT00819000?
This trial is currently completed. The enrollment target is 2,878 participants. The study started on 2008-12. Estimated completion is 2013-01.
What conditions does trial NCT00819000 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00819000?
The interventions under investigation include: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b (DRUG).
Who is sponsoring clinical trial NCT00819000?
This trial is sponsored by Teva Neuroscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00819000 being conducted?
This trial has 3 study locations across Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.